C21
Idiopathic Pulmonary Fibrosis
Clinical trials
2
Developer
Vicore Pharma AB
Overview
C21 is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 2 tracked IPF clinical trials.
C21 clinical trials
Explore related
Medical disclaimer. This page summarizes research about C21 for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.